FCGR1A and inflammatory bowel disease: We observed that PBMCs from IBD patients who initially did not respond to IFX therapy displayed significantly higher levels of CD64 and slightly elevated levels of both CD32 and CD16 as compared to healthy individuals, which was partially supportive to the observations reported earlier [22].